Tofacitinib in Acute Severe Ulcerative Colitis (TACOS): A Randomized Controlled Trial

医学 托法替尼 溃疡性结肠炎 安慰剂 优势比 内科学 置信区间 随机化 随机对照试验 人口 英夫利昔单抗 外科 类风湿性关节炎 疾病 替代医学 环境卫生 病理
作者
Arshdeep Singh,Manjeet Kumar Goyal,Vandana Midha,Ramit Mahajan,Kirandeep Kaur,Yogesh Gupta,Dharmatma Singh,Namita Bansal,Ramandeep Kaur,Shivam Kalra,Omesh Goyal,Varun Mehta,Ajit Sood
出处
期刊:The American Journal of Gastroenterology [Lippincott Williams & Wilkins]
卷期号:119 (7): 1365-1372 被引量:44
标识
DOI:10.14309/ajg.0000000000002635
摘要

INTRODUCTION: Intravenous corticosteroids are the mainstay of treatment of patients hospitalized with acute severe ulcerative colitis (ASUC). However, 30%–40% of the patients are refractory to corticosteroids. We investigated whether addition of tofacitinib to corticosteroids improved the treatment responsiveness in patients with ASUC. METHODS: This single-center, double-blind, placebo-controlled trial randomized adult patients with ASUC (defined by the Truelove Witts severity criteria) to receive either tofacitinib (10 mg thrice daily) or a matching placebo for 7 days while continuing intravenous corticosteroids (hydrocortisone 100 mg every 6 hours). The primary end point was response to treatment (decline in the Lichtiger index by >3 points and an absolute score <10 for 2 consecutive days without the need for rescue therapy) by day 7. The key secondary outcome was the cumulative probability of requiring initiation of infliximab or undergoing colectomy within 90 days following randomization. All analyses were performed in the intention-to-treat population. RESULTS: A total of 104 patients were randomly assigned to a treatment group (53 to tofacitinib and 51 to placebo). At day 7, response to treatment was achieved in 44/53 (83.01%) patients receiving tofacitinib vs 30/51 (58.82%) patients receiving placebo (odds ratio 3.42, 95% confidence interval 1.37–8.48, P = 0.007). The need for rescue therapy by day 7 was lower in the tofacitinib arm (odds ratio 0.27, 95% confidence interval 0.09–0.78, P = 0.01). The cumulative probability of need for rescue therapy at day 90 was 0.13 in patients who received tofacitinib vs 0.38 in patients receiving placebo (log-rank P = 0.003). Most of the treatment-related adverse effects were mild. One patient, receiving tofacitinib, developed dural venous sinus thrombosis. DISCUSSION: In patients with ASUC, combination of tofacitinib and corticosteroids improved treatment responsiveness and decreased the need for rescue therapy.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
生生不息发布了新的文献求助10
刚刚
刚刚
1秒前
朝天椒发布了新的文献求助10
6秒前
Ava应助孙季沅采纳,获得10
7秒前
11秒前
科研通AI5应助舒适路人采纳,获得30
11秒前
从容的巧曼完成签到 ,获得积分10
15秒前
wssamuel完成签到 ,获得积分10
16秒前
张慧杰完成签到,获得积分10
17秒前
大大小小发布了新的文献求助10
18秒前
丘比特应助Wang采纳,获得10
18秒前
开庆完成签到,获得积分10
18秒前
星点完成签到 ,获得积分10
19秒前
维恰完成签到 ,获得积分10
19秒前
19秒前
20秒前
21秒前
朝天椒完成签到,获得积分10
21秒前
21秒前
华仔应助生生不息采纳,获得10
23秒前
BulingQAQ完成签到,获得积分20
23秒前
SciGPT应助舒适路人采纳,获得10
24秒前
三岁居居发布了新的文献求助10
25秒前
72发布了新的文献求助10
27秒前
5001完成签到,获得积分10
27秒前
27秒前
不摇碧莲发布了新的文献求助10
27秒前
hustscholar发布了新的文献求助10
28秒前
29秒前
小蘑菇应助科研通管家采纳,获得10
29秒前
科研通AI5应助科研通管家采纳,获得10
29秒前
FashionBoy应助科研通管家采纳,获得10
29秒前
桐桐应助科研通管家采纳,获得10
29秒前
29秒前
29秒前
30秒前
twk发布了新的文献求助10
30秒前
科研通AI5应助xiubo128采纳,获得10
33秒前
SYLH应助整齐的香之采纳,获得50
33秒前
高分求助中
Les Mantodea de Guyane Insecta, Polyneoptera 2500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
Technologies supporting mass customization of apparel: A pilot project 450
A China diary: Peking 400
Brain and Heart The Triumphs and Struggles of a Pediatric Neurosurgeon 400
Cybersecurity Blueprint – Transitioning to Tech 400
Mixing the elements of mass customisation 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 物理 生物化学 纳米技术 计算机科学 化学工程 内科学 复合材料 物理化学 电极 遗传学 量子力学 基因 冶金 催化作用
热门帖子
关注 科研通微信公众号,转发送积分 3784436
求助须知:如何正确求助?哪些是违规求助? 3329565
关于积分的说明 10242565
捐赠科研通 3044992
什么是DOI,文献DOI怎么找? 1671494
邀请新用户注册赠送积分活动 800371
科研通“疑难数据库(出版商)”最低求助积分说明 759391